Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion

DRUG3 trials

Sponsors

Ziekenhuis Aan De Stroom, Medica Scientia Innovation Research S.L., Centre Regional Lutte Contre Le Cancer

Conditions

HER2- positive breast cancerProstate cancermetastatic breast cancer

Phase 2

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

RecruitingCTIS2022-501551-90-00

Ziekenhuis Aan De StroomProstate cancer

Start: 2023-12-13Target: 583Updated: 2026-01-23

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy The PHERGain study.

Active, not recruitingCTIS2023-509923-42-00

Medica Scientia Innovation Research S.L.HER2- positive breast cancer

Start: 2017-07-06Target: 345Updated: 2025-11-25

A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study

Not yet recruitingCTIS2024-516576-15-00

Centre Regional Lutte Contre Le Cancermetastatic breast cancer

Target: 224Updated: 2025-12-02